Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AIM ImmunoTech (AIM) Cash from Operations (2018 - 2025)

Historic Cash from Operations for ImmunoTech (AIM) over the last 11 years, with Q3 2025 value amounting to -$5.1 million.

  • ImmunoTech's Cash from Operations fell 6331.19% to -$5.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$12.9 million, marking a year-over-year increase of 3752.84%. This contributed to the annual value of -$14.9 million for FY2024, which is 2999.48% up from last year.
  • ImmunoTech's Cash from Operations amounted to -$5.1 million in Q3 2025, which was down 6331.19% from -$1.5 million recorded in Q2 2025.
  • ImmunoTech's 5-year Cash from Operations high stood at -$1.5 million for Q2 2025, and its period low was -$9.8 million during Q4 2023.
  • In the last 3 years, ImmunoTech's Cash from Operations had a median value of -$3.7 million in 2023 and averaged -$4.1 million.
  • Its Cash from Operations has fluctuated over the past 5 years, first skyrocketed by 5946.92% in 2024, then crashed by 6331.19% in 2025.
  • ImmunoTech's Cash from Operations (Quarter) stood at -$9.8 million in 2023, then skyrocketed by 59.47% to -$4.0 million in 2024, then fell by 28.42% to -$5.1 million in 2025.
  • Its Cash from Operations was -$5.1 million in Q3 2025, compared to -$1.5 million in Q2 2025 and -$2.4 million in Q1 2025.